GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Operating Margin %

InflaRx NV (InflaRx NV) Operating Margin %

: -725,500.00% (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. InflaRx NV's Operating Income for the three months ended in Dec. 2023 was $-14.51 Mil. InflaRx NV's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, InflaRx NV's Operating Margin % for the quarter that ended in Dec. 2023 was -725,500.00%.

The historical rank and industry rank for InflaRx NV's Operating Margin % or its related term are showing as below:

IFRX' s Operating Margin % Range Over the Past 10 Years
Min: -72288.06   Med: -70975.36   Max: -70975.36
Current: -72288.06


IFRX's Operating Margin % is ranked worse than
97.56% of 1025 companies
in the Biotechnology industry
Industry Median: -179.29 vs IFRX: -72288.06

InflaRx NV's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

InflaRx NV's Operating Income for the three months ended in Dec. 2023 was $-14.51 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-48.43 Mil.


InflaRx NV Operating Margin % Historical Data

The historical data trend for InflaRx NV's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -70,975.36

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -18,309.23 -725,500.00

Competitive Comparison

For the Biotechnology subindustry, InflaRx NV's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, InflaRx NV's Operating Margin % distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Operating Margin % falls into.



InflaRx NV Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

InflaRx NV's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-48.973 / 0.069
=-70,975.36 %

InflaRx NV's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-14.51 / 0.002
=-725,500.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV  (NAS:IFRX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


InflaRx NV Operating Margin % Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (InflaRx NV) Headlines

From GuruFocus

InflaRx Announces Public Offering of Ordinary Shares

By sperokesalga sperokesalga 04-11-2023